Portfolio Design Labs LLC Purchases New Position in Bristol Myers Squibb Company $BMY

Portfolio Design Labs LLC purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 12,294 shares of the biopharmaceutical company’s stock, valued at approximately $708,000.

Several other large investors have also recently added to or reduced their stakes in the company. Northwestern Mutual Investment Management Company LLC boosted its holdings in shares of Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock worth $3,509,000 after acquiring an additional 172 shares in the last quarter. KCM Investment Advisors LLC raised its position in Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock valued at $1,126,000 after purchasing an additional 174 shares during the last quarter. Sandy Cove Advisors LLC raised its position in Bristol Myers Squibb by 4.7% in the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock valued at $227,000 after purchasing an additional 176 shares during the last quarter. Investment Research Partners LLC boosted its stake in Bristol Myers Squibb by 1.4% in the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock worth $708,000 after purchasing an additional 179 shares in the last quarter. Finally, ESG Planning DBA Harper Investing grew its holdings in shares of Bristol Myers Squibb by 1.3% during the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock worth $745,000 after purchasing an additional 180 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb
• Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update
• Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval
• Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility.
• Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis
• Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy
• Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology

Bristol Myers Squibb Trading Down 3.1%

Shares of NYSE BMY opened at $65.54 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The stock has a market cap of $133.88 billion, a price-to-earnings ratio of 14.44, a P/E/G ratio of 0.18 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company’s fifty day moving average is $60.35 and its 200-day moving average is $59.31.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Truist Financial restated a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Weiss Ratings raised shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. Finally, Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $66.06.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.